LivaNova's (LIVN) "Buy" Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of LivaNova (NASDAQ:LIVN - Free Report) in a research report sent to investors on Monday,Benzinga reports. The firm currently has a $64.00 price target on the stock.

A number of other equities research analysts also recently commented on LIVN. The Goldman Sachs Group lowered their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Barclays dropped their price objective on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research note on Friday, March 7th. StockNews.com cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 26th. Mizuho dropped their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus cut their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, LivaNova presently has an average rating of "Moderate Buy" and a consensus target price of $61.17.

Remove Ads

LivaNova Trading Down 2.3 %

Shares of NASDAQ:LIVN traded down $0.95 during trading on Monday, reaching $39.48. The stock had a trading volume of 1,140,685 shares, compared to its average volume of 597,857. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The stock has a market cap of $2.15 billion, a P/E ratio of 94.00 and a beta of 1.10. The business has a fifty day moving average price of $45.45 and a 200-day moving average price of $48.83. LivaNova has a fifty-two week low of $36.85 and a fifty-two week high of $64.48.

Institutional Investors Weigh In On LivaNova

Several large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its position in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after purchasing an additional 219 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of LivaNova by 1.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company's stock worth $780,000 after purchasing an additional 289 shares in the last quarter. Atria Investments Inc boosted its position in shares of LivaNova by 6.2% in the third quarter. Atria Investments Inc now owns 5,653 shares of the company's stock worth $297,000 after buying an additional 331 shares during the period. Xponance Inc. grew its stake in shares of LivaNova by 6.1% in the fourth quarter. Xponance Inc. now owns 7,762 shares of the company's stock valued at $359,000 after buying an additional 445 shares in the last quarter. Finally, Mariner LLC raised its holdings in shares of LivaNova by 8.4% during the 4th quarter. Mariner LLC now owns 5,741 shares of the company's stock valued at $266,000 after buying an additional 446 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.